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INTRODUCTION
Breast-conserving therapy (BCT) has recently be-
come a standard treatment for early breast cancer.
The local recurrence rate is decreased using post-
operative radiotherapy, which cures minute lesions
remaining within the breast (1). In recent years, an
increasing number of patients have received breast-
conserving surgery. Even locally advanced cancers
have received this treatment, following down-staging
with neo-adjuvant chemotherapy. The reported fre-
quency of radiation pneumonitis (RP), caused by ra-
diotherapy following breast-conserving surgery, var-
ies greatly ; cumulative incidence rates of 0.9-85%
have been reported (2-9). RP occurs locally, in a
limited field of an irradiated lung, at an early time
after irradiation(10). Among the pulmonary injuries
following radiotherapy of whole breast, the most
clinical significant pulmonary disorder is radiation-
induced bronchiolitis obliterans organizing pneu-
monia (BOOP) syndrome. Radiation-induced BOOP
syndrome is characterized by infiltrative shadow
expansions outside the irradiation field of lung and
migrates ; however, the frequency of radiation- in-
duced BOOP is low. Crestani described the follow-
ing factors for diagnosing radiation-induced BOOP
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syndrome (11) : (1) radiotherapy to the breast within
the past 12 months, (2) general and/or respiratory
symptoms lasting for longer than 2 weeks, (3) ra-
diographic lung infiltrations outside the radiation
port and (4) no evidence of a specific cause.
Previous clinical studies investigating RP have re-
ported on several factors involved in the pathogene-
sis of RP, including patient age, lung volume within
an irradiated field, chemotherapy before radiother-
apy, prescription of tamoxifen during radiotherapy
and smoking history (12-15). In the present study,
we evaluated the risk factor for RP, including ra-
diation-induced BOOP syndrome, induced by whole
breast irradiation following breast-conserving sur-
gery, with respect to patient background factors and
treatment regimens.
MATERIALS AND METHODS
Between January 2005 and April 2007, 472 patient
cases were subjected to tangential irradiation follow-
ing breast-conserving surgery at the Tokushima
University Hospital. We conducted follow-up obser-
vations for 454 of 472 patients with respect to the
occurrence of pulmonary damage using chest radio-
graphs. We excluded cases in which the chest wall
had been irradiated after mastectomy, and in which
irradiation on axilla and supraclavicular nodal re-
gions had been simultaneously performed. We in-
cluded only those cases in which whole breast tan-
gential irradiation had been performed. In these
cases, we performed statistical analyses for 423
breasts (413 cases) using a pulmonary dose-volume
histogram (DVH). DVH was calculated using a
three-dimensional treatment planning device (XiO,
ver. 4.33.02, manufactured by CMS). Patient char-
acteristics, treatment regimen and irradiation meth-
ods were included as variables on the analyses of the
risk factors for RP. In 10 cases, tangential irradia-
tion was performed simultaneously for both breasts
following breast-conserving surgery.
Patients
The patient background of 413 cases is shown
in Tables 1 and 2. With respect to chemotherapy,
neo-adjuvant chemotherapy was performed in 49
cases, pre-irradiation adjuvant chemotherapy in 5
cases and post-irradiation adjuvant chemotherapy
in 100 cases. Of the 313 cases in which endocrine
therapy was conducted, 130 concurrently received
both endocrine therapy and radiotherapy, whereas
Table 1. Patient characteristics (n=413)
Age (y), range (median) 24-84(52)
Side (right/left/bilateral) 212/191/10
Collagen vascular disease (yes/no) 6/407
Allergy disease and /or drug allergy (yes/no) 73/340
Diabetes (yes/no) 12/401
Smoking status (yes/no/unknown) 64/283/76
Usage of other medication unrelated to breast
cancer (yes/no) 126/297
Clinical stage (UICC)
0 54
I 206
II A 101
II B 46
III A 9
III B 3
III C 1
Histologic type
Noninvasive ductal carcinoma 52
Invasive ductal carcinoma 328
other 43
Operation
Lumpectomy 316
Quadrantectomy 105
other 2
Chemotherapy (yes/no) 143/283
pre-radiotherapy 54
post-radiotherapy 100
Endocrine therapy ( yes/no ) 313/98
antiestrogen drug 147
aromatase inhibitor 164
Concurrent endocrine therapy( yes/no ) 130/293
antiestrogen drug 47
aromatase inhibitor 87
Abbreviations : UICC=International Union Against Cancer.
Table 2. Radiation therapy details (n=423 breast)
Whole breast irradiation
50 Gy/25 fraction 423
Boost to tumor bed (yes/no)
10 Gy/5 fraction 114/309
Photon energy (4 MVX/6 MVX) 405/18
Wedge filter (yes/no) 422/1
Central lung distance (cm) 0.8-3.2 (1.8)
Field length, long axis (cm) 14.6-21.6 (17.9)
Field length, short axis (cm) 3.8-11.1 (6.8)
Ipsilateral lung V20Gy (mean : 9.6%)
1.8-9.6 (%) 213
9.7-18.8(%) 210
Ipsilateral lung V10Gy (mean : 12.2%)
2.9-12.2(%) 214
12.3-22.3 (%) 209
Bilateral lung V20Gy (mean : 4.9%)
0.8-4.9 (%) 213
4.9-14.2 (%) 210
Bilateral V10Gy (mean : 6.2%)
1.3-6.2(%) 213
6.3-17.5(%) 210
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oral administration was started after radiotherapy in
183 cases. Anti-estrogen agents were administered
in 147 cases and aromatase inhibitors (AIs) in 164
cases. In cases where medication was changed dur-
ing the follow-up period, the medication that was
administered initially was recorded. With regard to
patient history, there were 6 cases of collagen dis-
ease, 30 cases of double cancer (18 cases of contra-
lateral breast cancer), 3 cases of BCT experience
for contralateral breast cancer and 73 cases of al-
lergic disease. The use of treatment planning CT
confirmed the absence of active pulmonary disease
in any of these cases at the beginning of radiother-
apy. All patients provided written informed consent
before radiotherapy.
Radiotherapy
We used 4 or 6 million volt X-rays for the radio-
therapy of remaining breasts, and conducted tan-
gential irradiation of 50 Gy/25 fraction/5 weeks on
all breasts in accordance with the Hinge method
(using 4 or 6 million volt X-rays, wedge 15). A 15
wedge filter was used arbitrarily to equalize the dose
distribution. The PRIMUS KD-2 (manufactured by
Siemens/Toshiba) was used as a linear accelerator.
With regard to 114 cases where the resection mar-
gins were positive, boost therapy of 10 Gy/5 frac-
tions was added to the tumor beds using electron
beams with appropriate energy.
Follow-up
We started the follow up examination with chest
radiographs of every 3 months for 1 year after com-
pletion of radiotherapy. Based on previous study,
radiation pneumonitis tends to occur shortly after
the completion of radiotherapy(10). So, after the
1 year follow-up period using chest radiograph,
patient’s status were obtained by hospital records
or interviews. When the chest radiographs showed
an abnormal shadow, we performed the further ex-
amination using chest CT in order to evaluate the
RP and confirm the grade of RP. The median pe-
riod of the follow-up observation after completion
of radiotherapy was 11.9 months (range : 2.9-41.6
months). The grade of RP was evaluated in accor-
dance with version 3.0 of the NCI Common termi-
nology Criteria for Adverse Events (CTC/AE ver.
3.0).
Statistical analysis
We analyzed risk factors for RP using univariate
analysis (univariate Cox regression model) and
multivariate analysis (Cox regression model). The
variables analyzed were : patient age, history of aller-
gic disease, the simultaneous use of systemic medi-
cine (except medicine being used for the treatment
of breast cancer), tumor location (every lesion lo-
cated at the border between the outside and the in-
side of a breast was regarded as being inside), op-
erative method, presence and timing of chemother-
apy, whether the endocrine therapy was used during
radiotherapy or in stages, whether the type of drug
administered was an anti-estrogen agent or an AI, X-
ray energy, total irradiation dose, long and short axis
length of the radiation field, central lung distance
(CLD) measured from the axial image on the XiO
and the volume receiving more than 20 Gy (V20Gy),
as well as V10Gy, of ipsilateral and bilateral lungs. Sta-
tistical significance was defined as P0.05 (Figs.
1, 2).
Fig. 2. The furthest distance between the posterior border of
the radiation field and the chest wall was measured from the axial
image of the treatment planning CT.
C : central lung distance (CLD) (cm).
Fig. 1. Digitally reconstructed radiography image of the three-
dimensional treatment planning device in the radiation field
A : long axis length of the radiation field (cm), B : short axis
length of the radiation field (cm)
At our hospital, the anterior border of the radiation field is set
at a distance of 1.5 cm from the skin surface of the nipple base
on the CT.
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RESULTS
Cumulative incidence of RP
Of the 423 breasts from 413 patients, 89 breasts
from 84 cases (21%) were diagnosed with RP, based
on the chest radiograph. According to the evaluation
of the grade of pneumonitis using CTC/AE ver. 3.0,
there were 77 cases (18.2%) of Grade 1 RP, 10 cases
(2.3%) of Grade 2, and 2 cases (0.5%) of Grade 3.
The age of patients diagnosed with RP ranged from
25 to 80 years (median : 50). Thirty-six cases had
RP in their left breasts and 53 in their right breasts.
Fifteen cases (16.8%) had a history of allergic dis-
ease and 17 (19.1%) had a smoking history. In 32
cases (35.9%), simultaneous medication was done,
in addition to that for breast cancer treatment dur-
ing radiotherapy. In 26 cases, lesions were found in-
side the breasts. In 60 cases, the T factor was T1 or
less, while in 60 cases, the N factor was N0. Accord-
ing to the staging classification, 49 cases were di-
agnosed stage I or below. The operative method of
63 cases was lumpectomy. 72 cases were treated
with endocrine therapy, of which 34 were treated
during the irradiation period. With respect to fac-
tors regarding radiotherapy, 82 cases were treated
with 4 MV X-rays, whereas 28 cases underwent
boost irradiation. The long axis length of the radia-
tion field was 14.6-21.6 cm (median : 17.9 cm) and
the short axis length was 3.8-11.1 cm (median : 6.8
cm) ; the CLD was 0.8-3.2 cm (median : 1.8 cm).
Radiation-induced BOOP syndrome
In the present analysis, radiation-induced BOOP
syndrome was observed in 12/413 cases (2.9%). All
cases of Grade 2 RP or greater developed radiation-
induced BOOP syndrome. The age of the patients
ranged from 39 to 72 years (median : 50 years old).
The clinical symptoms were fever (10 cases), cough-
ing (12 cases), decrease in oxygen saturation (8
cases) and sense of dyspnea (8 cases). The timing
of the pathogenesis was 2.5-23.1 months after the
end of treatment (median : 3.6 months)., Abnormal
shadows were observed on the chest radiographs
taken 3 months after the completion of radiotherapy
in all cases, except for one case, in which RP oc-
curred after 23.1 months. Bronchoscopy was per-
formed in 8 cases. The total cell number in bron-
choalveolar lavage fluid was increased in 7/8 cases.
The transbronchial lung biopsy specimens in all 8
cases diagnosed pathologically as organized pneu-
monia. Of the 12 cases, steroid administration was
implemented in 7 cases, resulting in rapid improve-
ment of symptoms. However, recurrence of symp-
toms due to the decrease or suspension of the ster-
oid administration was observed in 4 cases. The
duration of the steroid administration was 5.8-41.4
months (median : 12.3 months) (Table 3).
A 39 year-old woman, in whom RP occurred after
Table 3. Clinical characteristics of 12 patients with radiation- induced BOOP syndrome
Patient Age(y) side
Endocrine
therapy
Endocrine
therapy
(drug)
Chemotherapy dose CLD(cm)
Short
axis
(cm)
Ipsilateral
V20 Gy
(%)
Steroid Steroid(relapse)
Onset,
After RT
(month)
Duration
of steroid
(month)
1 40 right sequential Tamoxifen - 60 2.4 8.2 12.05 + - 3.2 5.8
2 52 left sequential Anastrozole - 50 2.0 6.6 13.93 + + 4.4 12
3 46 right none - - 50 2.1 7.3 14.00 - - 2.7 -
4 53 right concurrent Anastrozole pre+post RT 60 2.0 5.7 7.89 - - 6.0 -
5 48 left sequential Tamoxifen - 50 1.7 6.7 8.88 + + 2.5 41.1
6 72 right sequential Anastrozole - 60 2.0 6.4 8.35 + - 6.9 11.1
7 47 right sequential Tamoxifen - 60 1.9 7.3 9.13 - - 3.6 -
8 59 left sequential Anastrozole - 50 1.7 6.3 10.56 + + 3.2 35.8
9 69 right sequential Anastrozole - 60 1.8 8.8 10.05 + + 3.0 23.8
10 59 left none - - 50 2.3 6.7 12.14 - - 3.7 -
11 44 right concurrent Tamoxifen - 60 2.1 6.6 8.74 - - 3.7 -
12 39 left concurrent Tamoxifen - 50 1.7 5.7 9.05 + - 23.1 12.2
Abbreviations : BOOP=bronchiolitis obliterans organizing pneumonia ; RT=radiotherapy ; CLD=central lung distance
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23.1 months, had been taking immunosuppressive
agents for a long period due to chronic rheumatoid
arthritis. Moreover, radiation treatment planning
CT did not show any lesions in her lung fields, and
chest radiography taken 3 months after radiotherapy
did not reveal any obvious abnormal shadows. Ad-
ministration of the immunosuppressive agents was
partially suspended 20 months after the completion
of the radiotherapy. Moreover, an increased den-
sity area that was corresponding to the irradiation
field, appeared in the lung field on the CT images
at 22 months after radiotherapy. However, she
complained of no symptoms at that time. Fever and
coughing appeared 23 months after the completion
of radiotherapy. Chest radiography revealed an in-
filtrative shadow expanding outside the radiation
field. She was diagnosed with organized pneumonia
using a bronchoscope, and was clinically diagnosed
with radiation-induced BOOP syndrome. Therefore,
we started steroid administration and her symptoms
improved rapidly. Although this case did not match
the criteria proposed by Crestani in terms of the tim-
ing of the pathogenesis(11), we extrapolated that RP
can occur more than 1 year after irradiation pro-
vided that there are special conditions, such as the
use of immunosuppressive agents, as in this case
(Fig. 3).
Risk factors for RP
The univariate analysis detected significant dif-
ferences in the following factors for incidence of
RP of Grade 1 or greater : chemotherapy after ra-
diotherapy (p=0.005), chemotherapy in all the pe-
riods including before and after radiotherapy (p=
0.001), short axis of the radiation field (6.8 cm ; p=
0.002), CLD (1.8 cm ; p=0.002), N factors (N1 ;
A C
B D
Fig. 3. A 39-year-old woman had been continuously taking immunosuppressive agents for the treatment of chronic rheumatoid arthri-
tis. No abnormalities were recognized from the treatment planning CT before irradiation or from the chest radiograph taken 3 months
after irradiation. Partial suspension of immunosuppressive agent administration 20 months after irradiation led to the detection of a
localized concentration increasing region by chest CT conducted 22 months after irradiation. No symptoms were indicated at this
point. Chest CT conducted 23 months after irradiation, however, revealed a clinical symptom consisting of infiltrative shadows and
ground-glass opacity expanding outside the radiation field. They were diagnosed as organized pneumonia by bronchoscopy (A, B :
CT performed 20 months after irradiation, C, D : CT performed 23 months after irradiation).
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p=0.029), and use of AIs (p=0.028) (Table 4, 5).
The cases of Grade 2 or greater were analyzed in
the same manner. The univariate analysis detected
significant differences only in CLD (1.8 cm ; p=
Table 4. Univariate analysis of patient factors associated with Radiation pneumonitis
Factor RP (n=89) RR p -value 95% CI
Age 50 y 33(191) 0.76 0.20 0.49-1.2
51 y 56(232) 1
Side left 36(201) 0.73 0.15 0.48-1.1
right 53(222) 1
Tumor factor T0,Tis,T1 60(301) 0.84 0.43 0.54-1.3
T2,T3,T4 29(122) 1
Node factor N0 62(331) 0.60 0.03 0.39-0.95
N1,N2,N3 27(92) 1
Clinical stage I stage 49(263) 0.73 0.14 0.48-1.1
IIA stage 40(160) 1
Location (region) inner side 26(161) 0.65 0.06 0.41-1.0
outer side 63(259) 1
unknown 0(3)
Operation lumpectomy 63(316) 0.76 0.24 0.48-1.2
quadrantectomy 26(105) 1
Allergic disease (+) 15(73) 0.96 0.89 0.55-1.7
(-) 74(350) 1
Usage of other medication unrelated to breast cancer (+) 32(126) 1.23 0.34 0.80-1.9
(-) 57(297) 1
Smoking status (+) 17(64) 1.14 0.70 0.65-1.9
(-) 66(283) 1
unknown 0(76)
Chemotherapy (+) 44(143) 1.98 0.01 1.3-3.0
(-) 45(280) 1
chemotherapy (pre-RT) (+) 14(54) 1.27 0.41 0.72-2.3
(-) 75(369) 1
chemotherapy (post-RT) (+) 32(100) 1.87 0.01 1.2-2.9
(-) 57(323) 1
Endocrine therapy (+) 72(313) 1.39 0.23 0.82-2.4
(-) 17(98) 1
unknown 0(12)
antiestrogen drug (+) 26(148) 0.79 0.32 0.50-1.3
(-) 63(275) 1
aromatase inhibitor (+) 45(164) 1.59 0.03 1.1-2.4
(-) 44(259) 1
(Concurrent endocrine therapy) concurrent 34(130) 1.34 0.20 0.85-2.1
sequential 38(183) 1
antiestrogen drug concurrent 10(47) 1.08 0.81 0.56-2.1
other 79(376) 1
aromatase inhibitor concurrent 24(83) 1.59 0.05 0.99-2.5
other 65(340) 1
Abbreviations : RP=radiation pneumonitis ; RT=radiotherapy ; CLD=central lung distance ; RR=relative risk ; CI=confidence interval.
Table 5. Univariate analysis of radiotherapy factors associated with Radiation pneumonitis
Factor RP (n=89) RR p -value 95% CI
Energy 4 MVX 82(405) 0.58 0.17 0.27-1.3
6 MVX 7(18) 1
Radiation dose 50 Gy 61(309) 0.76 0.23 0.49-1.2
60 Gy 25(114) 1
Field length (long axis) (mean : 17.9 cm) 14.6-17.9 45(212) 1.01 0.97 0.67-1.5
18.0-21.6 44(211) 1
Field length (short axis) (mean : 6.8 cm) 3.8-6.8 33(217) 0.51 0.01 0.33-0.79
6.8-11.1 56(206) 1
CLD (mean : 1.8 cm) 0.8-1.8 42(222) 0.51 0.01 0.35-0.80
1.9-3.1 47(112) 1
Ipsilateral lung V20Gy (mean : 9.6%) 1.8-9.6 (%) 36(213) 0.67 0.13 0.48-1.1
9.7 -18.8 (%) 53(210) 1
Ipisilateral lung V10Gy (mean : 12.2%) 2.9-12.2 (%) 37(214) 0.69 0.09 0.45-1.1
12.3-22.3 (%) 52(209) 1
Bilateral lung V20Gy (mean : 4.9%) 0.8-4.9 (%) 38(213) 0.75 0.17 0.49-1.1
4.9 -14.2 (%) 51(210) 1
Bilateral ling V10Gy (mean : .2%) 1.3-6.2 (%) 39(213) 0.77 0.23 0.51-1.2
6.3 -17.5 (%) 50(210) 1
Abbreviations : RP=radiation pneumonitis ; RT=radiotherapy ; CLD=central lung distance ; RR=relative risk ; CI=confidence interval.
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0.043) and in the operative method (lumpectomy ;
p=0.007). Other than these factors, the patients who
underwent chemotherapy (p=0.090) and the patients
who received radiation dose of 60 Gy (p=0.080)
tended to appear RP, but it was not statistically sig-
nificant (Table 6, 7).
Table 6. Univariate analysis of patient factors associated with RP of Grade 2 or greater, diagnosed as radiation- induced BOOP
syndrome
Factor BOOP (n=12) RR p -value 95% CI
Age 50 y 6(191) 1.30 0.65 0.42-4.0
51 y 6(232) 1
Side left 5(201) 0.77 0.66 0.24-2.4
right 7(222) 1
Tumor factor T0,Tis,T1 9(301) 1.25 0.74 0.34-4.6
T2,T3,T4 3(122) 1
Node factor N0 11(331) 3.20 0.27 0.41-24.8
N1,N2,N3 1(92) 1
Clinical stage I stage 9(263) 1.87 0.35 0.51-6.9
IIA stage 3(160) 1
Location (region) inner side 3(161) 0.54 0.35 0.15-2.0
outer side 9(259) 1
unknown 0(3)
Operation lumpectomy 5(316) 0.21 0.01 0.07-0.65
quadrantectomy 7(105) 1
other 0(2)
Allergic disease (+) 4(73) 2.35 0.16 0.71-7.8
(-) 8(350) 1
Usage of other medication unrelated to breast cancer (+) 3(126) 0.73 0.63 0.20-2.7
(-) 9(297) 1
Smoking status (+) 1(64) 0.38 0.36 0.05-3.0
(-) 11(283) 1
unknown 0(76)
Chemotherapy (+) 1(143) 0.17 0.09 0.02-1.3
(-) 11(280) 1
chemotherapy (pre-RT) (+) 1(54) 0.63 0.66 0.08-4.9
(-) 11(369) 1
chemotherapy (post-RT) (+) 1(100) 0.27 0.21 0.04-2.1
(-) 11(323) 1
Endocrine therapy (+) 10(313) 1.55 0.54 0.34-7.1
(-) 2(98) 1
unknown 0(12)
antiestrogen drug (+) 5(148) 1.32 0.63 0.42-4.2
(-) 7(275) 1
aromatase inhibitor (+) 5(164) 1.06 0.92 0.34-3.3
(-) 7(259) 1
(Concurrent endocrine therapy) concurrent 4(130) 1.02 0.98 0.29-2.6
sequential 6(183) 1
antiestrogen drug concurrent 2(47) 1.70 0.50 0.37-7.7
other 10(376) 1
aromatase inhibitor concurrent 2(83) 0.82 0.80 0.18-3.7
other 10(340) 1
Abbreviations : BOOP=bronchiolitis obliterans organizing pneumonia ; RT=radiotherapy ; CLD=central lung distance ; RR=relative
risk ; CI=confidence interval.
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The multivariate analysis detected significant dif-
ferences in the following factors for incidence of
Grade 1 or greater RP : short axis length (6.8 cm ;
p=0.024) and CLD (1.8 cm ; p=0.021) (Table 8).
The multivariate analysis of the RP cases of Grade
2 or greater detected a significant difference only in
CLD (1.8 cm ; p=0.027) (Table 9).
Table 7. Univariate analysis of radiotherapy factors associated with RP of Grade 2 or greater, diagnosed as radiation- induced
BOOP syndrome
Factor BOOP (n=12) RR p -value 95% CI
Energy 4 MVX 12(405)
6 MVX 0(18)
Radiation dose 50 Gy 6(309) 0.36 0.08 0.12-1.1
60 Gy 6(114) 1
Field length (long axis) (mean : 17.9 cm) 14.6-17.9 6(212) 1.00 0.99 0.32-3.1
18.0-21.6 6(211) 1
Field length (short axis) (mean : 6.8 cm) 3.8-6.8 8(217) 1.76 0.36 0.53-5.9
6.8 -11.1 4(206) 1
CLD (mean : 1.8 cm) 0.8-1.8 4(222) 0.29 0.04 0.09-0.96
1.9-3.1 8(112) 1
Ipsilateral lung V20Gy (mean : 9.6%) 1.8-9.6 (%) 7(213) 1.02 0.97 0.32-3.2
9.7 -18.8 (%) 5(210) 1
Ipisilateral lung V10Gy (mean : 12.2%) 2.9-12.2 (%) 6(214) 1.01 0.99 0.33-3.1
12.3-22.3 (%) 6(209) 1
Bilateral lung V20Gy (mean : 4.9%) 0.8-4.9 (%) 6(213) 1.04 0.95 0.33-3.2
4.9 -14.2 (%) 6(210) 1
Bilateral ling V10Gy (mean : 6.2%) 1.3-6.2 (%) 6(213) 1.04 0.95 0.33-3.2
6.3 -17.5 (%) 6(210) 1
Abbreviations : BOOP=bronchiolitis obliterans organizing pneumonia ; RT=radiotherapy ; CLD=central lung distance ; RR=relative
risk ; CI=confidence interval.
Table 8. Multivariate analysis of factors associated with RP
Factor RP (n=89) RR p -value 95% CI
Node factor N0 62(331) 1.08 0.78 0.61-1.9
N1,N2,N3 27(92) 1
Location (region) inner side 26(161) 0.76 0.25 0.48-1.2
outer side 63(259) 1
unknown 0(3)
Chemotherapy (+) 44(143) 1.70 0.16 0.81-3.6
(-) 45(280) 1
chemotherapy (post-RT) (+) 32(100) 1.32 0.45 0.65-2.7
(-) 57(323) 1
aromatase inhibitor (+) 45(164) 1.39 0.24 0.80-2.4
(-) 44(259) 1
aromatase inhibitor concurrent 24(83) 1.31 0.41 0.69-2.5
other 65(340) 1
Field length (short axis) (mean : 6.8 cm) 3.8-6.8 33(217) 0.60 0.02 0.39-0.94
6.8-11.1 56(206) 1
CLD (mean : 1.8 cm) 0.8-1.8 42(222) 0.58 0.02 0.36-0.92
1.9-3.1 47(112) 1
Ipsilateral lung V20Gy (mean : 9.6%) 1.8-9.6 (%) 36(213) 0.89 0.63 0.56-1.4
9.7 -18.8 (%) 53(210) 1
Abbreviations : RP=radiation pneumonitis ; RT=radiotherapy ; CLD=central lung distance ; RR=relative risk ; CI=confidence interval.
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DISCUSSION
The frequency of pulmonary damage caused by
radiotherapy following breast cancer surgery, includ-
ing RP occurring at an early time after irradiation
and fibrosis occurring at a late time, varies greatly
from 0.9% to 85%, depending on reports. Naturally,
the detection rates differ between chest radiography
and chest CT. According to a previous report, CT
evaluation 3 months after radiotherapy showed a
frequency of Grade 1 or greater RP of 37% (14). HR-
CT evaluation, 4 months after radiotherapy, also de-
tected changes in pulmonary parenchyma within ra-
diation fields in 85% of cases(7). In general, the fre-
quency of RP evaluated by chest radiograph is 0.9-
47%. In the present study, 21% of patients showed RP
on the chest radiograph at 3 months after comple-
tion of radiotherapy. The previous reports, however,
also involve local-regional radiotherapy on supracla-
vicular and axilla fields, as well as chest-wall irra-
diation after mastectomy and differ slightly from our
study with respect to the subjects (2, 6, 14, 16, 17).
BOOP was reported in 1985 by Epler, et al. It pre-
sents symptoms such as coughing, sense of dyspnea,
fever and chest pain. On images, it shows patchy
consolidation accompanied by ground-glass opaci-
ties. Histological characteristics include polypoid
masses of granulation tissue in the lumens of small
airways, alveolar ducts and some alveoli. Although
it can be classified into idiopathic and secondary,
the majority of cases are usually idiopathic. The fre-
quency of radiation-induced BOOP syndrome fol-
lowing breast-conserving surgery of breast cancer
has been reported as 2.3% (15), 2.4% (13) and 2.5%
(12). In the present study, a similar incidence of
2.9% was obtained as a result. It included one atypi-
cal case among the 12 cases in which clinically prob-
lematic RP of Grade 2 or greater presented. Apart
from this case, however, clinical symptoms requir-
ing treatment did not appear before the period of
2.5-6.9 months after radiotherapy. In all cases, slight
abnormal shadows can be detected on the chest ra-
diographs at the 3-month after radiotherapy. It is
considered that RP and radiation-induced BOOP
syndrome are two different clinical conditions. RP
results from the direct influence of irradiation,
whereas radiation-induced BOOP syndrome is be-
lieved to be caused by autoimmunization induced
indirectly by irradiation (10-13, 18, 19). Neverthe-
less, at the onset of radiation-induced BOOP syn-
drome, infiltrative shadows resembling ground-glass
opacity, in areas corresponding to radiation fields,
begin to appear. They then develop into infiltrative
shadows expanding outside the radiation field areas.
In the present study, there were hardly any clinical
symptoms 3 months after radiotherapy. However,
the next follow-up observations indicated 7 cases of
exacerbated symptoms of Grade 2 or greater, de-
spite the fact that the CT taken at 3 months after ra-
diotherapy was only able to detect localized shadows
within the radiation field. This led us to believe that
conducting an evaluation 3 months after radiother-
apy was crucial.
There have been several reports analyzing the
factors concerning pathogenesis of RP and radia-
tion- induced BOOP syndrome caused by irradia-
tion following breast cancer surgery. There have
been 4 reports investigating radiation-induced BOOP
syndrome caused by irradiation after conserving
surgery (12, 13, 15, 20). However, no reports have
Table 9. Multivariate analysis of factors associated with Grade2 or greater pneumonitis, diagnosed as radiation- induced BOOP
syndrome
Factor BOOP (n=12) RR p -value 95% CI
Chemotherapy (+) 1(143) 0.17 0.09 0.02-1.3
(-) 11(280) 1
Radiation dose 50 Gy 6(309) 0.44 0.17 0.14-1.4
60 Gy 6(114) 1
Field length (short axis) (mean : 6.8 cm) 3.8-6.8 8(217) 1.55 0.49 0.45-5.3
6.8 -11.1 4(206) 1
CLD (mean : 1.8 cm) 0.8-1.8 4(222) 0.24 0.03 0.07-0.85
1.9-3.1 8(112) 1
Ipsilateral lung V20Gy (mean : 9.6%) 1.8-9.6 (%) 7(213) 1.64 0.43 0.48-5.6
9.7 -18.8 (%) 5(210) 1
Abbreviations : BOOP=bronchiolitis obliterans organizing pneumonia ; RT=radiotherapy ; CLD=central lung distance ; RR=relative
risk ; CI=confidence interval.
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been published investigating the effects of patient
background and treatment regimens on the patho-
genesis of Grade 1 RP. In the present study, we only
analyzed cases in which whole breast irradiation had
been performed and in which all radiotherapy tech-
nical factors had been evaluated. As for the relation-
ship between patient characteristics and RP, al-
though patient age has often been cited as a risk fac-
tor (2, 14, 20-24), no such relationship was estab-
lished in the present study. In agreement with pre-
vious reports, smoking history and the simultaneous
use of other medication were not identified as fac-
tors influencing risk of RP (3, 20, 25). The use of
radiotherapy and chemotherapy simultaneously in-
creases the risk of RP (9, 17), however, the risk in-
duced by the use of chemotherapy in stages varies
greatly among reports (15, 20, 26, 27). Our univari-
ate analysis also suggested that adjuvant chemother-
apy increases the risk of RP.
There are numerous reports indicating the in-
volvement of anti-estrogen agents in the pathogene-
sis of RP, especially tamoxifen (15, 21, 22, 28, 29).
In the present study, however, anti-estrogen agents
were not a significant variable for RP, whereas a
correlation was found with the use of AIs. Increasing
of RP patients who have used AIs might be related
to age because AIs are generally used in postmeno-
pausal women. With regard to radiotherapy factors,
breast and regional irradiation including supracla-
vicular and axilla (local-regional radiotherapy) is
considered to result in a higher frequency of RP
compared with whole breast irradiation (local radio-
therapy)(2, 6, 14, 16, 17). Lind, et al. have reported
that the risk of RP was significantly higher in local-
regional radiotherapy (4.1%) compared with local
radiotherapy (0.9%) (16). Kahan (14), likewise, has
reported that the incidence of RP and fibrosis were
2.5 times higher in regional irradiation. V20Gy was
reported to correlate with lung volume ; the more
V20Gy increased, the higher the incidence of RP (2,
14, 23). So we investigated only cases of breast ir-
radiation, the frequency of RP had no significant sta-
tistically correlation with V20Gy as well as V10Gy in the
present study. Previous reports, on the other hand,
took into consideration the regional irradiation, lead-
ing to the speculation that significant differences
were obtained due to the high influence of the re-
gional irradiation. There have also been several re-
ports indicating the involvement of CLD with RP (8,
9). Fernando, et al. (9) have reported the frequency
of RP as 4.6% in cases where CLD was 3 cm or
more. The present study also showed that CLD of
1.9 cm or more increased the risk of RP and radia-
tion-induced BOOP syndrome. Another result of the
present study was that the short axis length of the
radiation field correlated with RP in the univariate
and multivariate analyses. Although there have been
reports examining the long axis length of radiation
fields (15), it is difficult to compare the short axis
with other analyses owing to different operational
criteria among institutions. Nevertheless, RP is con-
siderably affected by the lung volume to be irradi-
ated, in the same way as CLD. The radiation dose
exhibited no significant difference, albeit a tendency
to correlate with the radiation-induced BOOP syn-
drome was observed. There are numerous reports
investigating risk factors for the RP and radiation-
induced BOOP syndrome. Though, in our study,
there are no significant differences with previously
suggested factors, such as age and the simultaneous
use of hormonal treatment. In multivariate analysis,
setting of the radiation field, such as CLD and short
axis length of the radiation field, was an important
factor. As for the timing of the RP, RP and radiation-
induced BOOP syndrome that required treatment
were detected on the chest radiography 3 months
after the treatment, suggesting that evaluation at this
stage is crucial. These results are suggesting that
we need to give careful attention to occurrence of
RP in around 3 months after completion of RT.
CONCLUSIONS
In the tangential irradiation of whole breast after
breast conserving surgery, the significant risk fac-
tors of RP are CLD (1.8 cm) and the short axis
length of the radiation field, as determined by multi-
variate analysis. The pathogenesis of radiation-in-
duced BOOP syndrome significantly correlated with
CLD. Therefore, the lung volume within the radia-
tion field proved to be a significant risk factor for
RP and radiation-induced BOOP syndrome. Regard-
ing follow-up after irradiation, the evaluation of chest
radiography 3 months after the end of irradiation
is postulated to be crucial.
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